Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.

A new report compiles the latest data and insight on scaling cell and gene therapy (CGT) effectively to improve patient access.

Viridian and Kissei Pharmaceutical have signed an exclusive partnership and license agreement for advancing veligrotug and VRDN-003.

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

MetrioPharm’s lead compound, MP1032, has received ODD from the European Medicines Agency (EMA) for treating DMD in children.

The FDA has approved Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH) for the treatment of adults with GHD.

The HS market across the 7MM is forecast to grow from $1.84bn in 2024 to $7.83bn in 2034, according to GlobalData.

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...